Security Snapshot

CYTOKINETICS INC - Common Stock (CYTK) Institutional Ownership

CUSIP: 23282W605

13F Institutional Holders and Ownership History from Q1 2014 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

359

Shares (Excl. Options)

117.31MFull value: 117,314,061 · shares · 30 Sep 2026

Price

$65.91

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
+4,571,932
Value change
+$206,520,343
Number of holders
359
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
139,514,961
SEC-reported price per share
$62.65
Insider filing price
$62.65
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • CYTK - CYTOKINETICS INC - Common Stock is tracked under CUSIP 23282W605.
  • 359 institutions reported positions in Q3 2026.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 480 to 359 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $13.66BFull value: $13,657,370,563 · USD · 30 Jun 2026
    to
    $7.7BFull value: $7,696,354,041 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 359 institutions filings for Q3 2026.

Open SEC evidence

Security key

23282W605

13F reference period

Q3 2026

13F holders

359

13D/G owners

5

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
5
Security
CYTK
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
T. Rowe Price Investment Management, Inc. 14% -9.4% $1,145,186,286 -$89,267,905 17,716,372 -7.2% T. Rowe Price Investment Management, Inc. 31 Dec 2025
WELLINGTON MANAGEMENT GROUP LLP 7.7% +52% $661,962,216 +$223,429,683 10,742,652 +51% Wellington Management Group LLP 30 Sep 2026
STATE STREET CORP 5.1% +8% $440,165,771 +$94,025,650 7,143,229 +27% STATE STREET CORPORATION 30 Sep 2026
VANGUARD CAPITAL MANAGEMENT LLC 5.2% $423,276,788 6,422,042 Vanguard Capital Management 31 Mar 2026
FMR LLC 3.9% -57% $447,127,030 -$501,481,150 5,248,580 -53% FMR LLC 30 Jun 2026
As of 30 Sep 2026, 359 institutional investors reported holding
117.31MFull value: 117,314,061 · shares · 30 Sep 2026
shares of CYTOKINETICS INC - Common Stock (CYTK). This represents 84% of the company’s total
139.51MFull value: 139,514,961 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
63%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
T. Rowe Price Investment Management, Inc. 14% 18,912,704 0.88% $1,246,537,000
WELLINGTON MANAGEMENT GROUP LLP 7.6% 10,590,381 0.12% $698,012,012
STATE STREET CORP 5.1% 7,143,229 0.01% $470,810,223
VANGUARD PORTFOLIO MANAGEMENT LLC 4.9% 6,799,536 0.02% $448,157,418
VANGUARD CAPITAL MANAGEMENT LLC 4.5% 6,266,419 0.01% $413,019,676
Avoro Capital Advisors LLC 3.5% 4,900,000 3.3% $322,959,000
BANK OF AMERICA CORP /DE/ 3.4% 4,735,328 0.02% $312,105,470
GEODE CAPITAL MANAGEMENT, LLC 2.7% 3,767,864 0.01% $248,385,218
Invesco Ltd. 2.2% 3,016,565 0.02% $198,821,799
RTW INVESTMENTS, LP 2.1% 2,862,003 1.9% $188,634,618
Capital Research Global Investors 1.8% 2,446,331 0.02% $161,237,676
GOLDMAN SACHS GROUP INC 1.3% 1,849,458 0.01% $121,897,775
Integral Health Asset Management, LLC 1.1% 1,600,000 4.5% $72,501,000
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 1.1% 1,576,135 0.34% $103,883,058
TWO SIGMA INVESTMENTS, LP 1.1% 1,565,456 0.07% $103,179,205
Pictet Asset Management Holding SA 0.99% 1,374,523 0.09% $90,568,817
ARMISTICE CAPITAL, LLC 0.85% 1,180,192 2.6% $77,786,455
Woodline Partners LP 0.79% 1,100,708 0.22% $72,547,664
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 0.77% 1,075,555 0.11% $70,889,830
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.75% 1,042,128 0.06% $68,686,656
Royalty Pharma Sub-Manager, LLC 0.7% 980,392 33% $64,617,637
VANGUARD FIDUCIARY TRUST CO 0.67% 930,360 0.01% $61,320,028
WCM INVESTMENT MANAGEMENT, LLC 0.65% 910,486 0.1% $59,764,301
Hood River Capital Management LLC 0.63% 884,605 0.49% $58,304,316
Fisher Asset Management, LLC 0.59% 818,832 0.02% $53,969,215

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
51
Headline period
Q3 2026
Rows shown
1-25 of 51
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 117,314,061 $7,696,354,041 +$206,520,343 $65.91 359
2026 Q2 160,386,683 $13,657,370,563 +$1,321,994,296 $85.19 480
2026 Q1 146,178,748 $9,630,470,011 +$408,062,408 $65.91 441
2025 Q4 139,445,035 $8,860,439,654 -$178,120,443 $63.54 431
2025 Q3 140,922,555 $7,744,502,918 +$248,284,955 $54.96 379
2025 Q2 137,672,960 $4,548,776,123 +$22,757,186 $33.04 308
2025 Q1 134,841,578 $5,424,137,644 +$124,956,259 $40.19 352
2024 Q4 131,310,237 $6,182,701,180 -$305,419,938 $47.04 342
2024 Q3 135,965,538 $7,179,495,863 -$22,095,980 $52.80 343
2024 Q2 135,538,659 $7,341,546,249 +$905,298,022 $54.18 341
2024 Q1 117,698,153 $8,252,737,252 +$191,436,420 $70.11 385
2023 Q4 114,281,648 $9,541,763,681 +$330,415,688 $83.49 344
2023 Q3 109,279,375 $3,219,564,491 +$24,845,219 $29.46 248
2023 Q2 108,724,328 $3,548,383,679 -$11,513,808 $32.62 252
2023 Q1 108,867,212 $3,829,923,005 +$81,444,143 $35.19 259
2022 Q4 106,503,991 $4,877,881,469 +$56,105,064 $45.82 271
2022 Q3 104,802,748 $5,076,619,614 -$48,250,542 $48.45 271
2022 Q2 105,856,945 $4,159,716,153 +$425,134,262 $39.29 255
2022 Q1 95,536,900 $3,516,647,768 +$153,742,395 $36.81 233
2021 Q4 91,314,688 $4,159,253,639 +$41,291,377 $45.58 244
2021 Q3 90,207,271 $3,220,707,699 +$496,552,275 $35.74 208
2021 Q2 75,530,208 $1,494,840,686 +$7,258,934 $19.79 184
2021 Q1 74,824,822 $1,739,406,944 +$58,909,832 $23.26 185
2020 Q4 72,927,397 $1,515,101,565 +$2,994,280 $20.78 174
2020 Q3 68,793,341 $1,486,919,340 +$223,796,678 $21.65 176
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .